Life Sciences, a leading medical device distributor and sales organization, is proud to announce a groundbreaking five-year partnership with Heron Therapeutics, Inc
Life Sciences, a leading medical device distributor and sales organization, is proud to announce a groundbreaking five-year partnership with Heron Therapeutics, Inc. This strategic collaboration aims to extend the sales network for ZYNRELEF® extended-release solution, a revolutionary pain-reducing product for orthopedic surgery patients.
As the largest private orthopedic, spine, and sports medicine device distributorship in the United States, CrossLink boasts a 45-year legacy of excellence. Their experienced sales, operations, and logistics teams are dedicated to the foundational goal of improving patient outcomes, making them the ideal partner for Heron Therapeutics.
Following discussions with several surgeons CrossLink who have reported positive results with ZYNRELEF, a substantial opportunity has emerged to broaden its accessibility to both surgeon customers and patients. The CrossLink sales force, known for its enduring track record of performance, played a decisive role in Heron’s choice to award this contract. This recognition underscores the confidence in CrossLink’s ability to effectively promote and distribute ZYNRELEF, further solidifying the collaborative success anticipated in the coming years.
Kicking off in phases, starting regionally and expanding nationally, CrossLink will play a pivotal role in this partnership, overseeing the promotion of ZYNRELEF for orthopedic indications. With approximately 650 representatives being added to Heron’s sales network in the next year, CrossLink is set to be a driving force in the expansion of ZYNRELEF’s reach.
“We are excited about the partnership with Heron and its upcoming potential expansion of the ZYNRELEF label and the vial-access needle (VAN) which will streamline the product preparation. We have seen first-hand the impact that ZYNRELEF can have on post-operative pain, and our team is excited to deliver ZYNRELEF to more patients across the country,” said Thomas Fleetwood, CrossLink CEO.
Explore the details of this partnership and stay updated on the latest developments through CrossLink’s website.